双氢青蒿素逆转人结肠癌耐药细胞耐药性的研究  

Reversal of Multidrug Resistance of Human Colon Cancer Cells by Dihydroartemisin

作　　者：陶鹏宇[1,2] 施明杰[1] 黄永焯[1] 王慧媛[1] 徐勤[2] 

机构地区：[1]中国科学院上海药物研究所,上海201203 [2]广州中医药大学热带医学研究所,广东广州510405

出　　处：《广州中医药大学学报》2016年第5期698-703,共6页Journal of Guangzhou University of Traditional Chinese Medicine

基　　金：国家自然科学基金资助项目(编号:81402883);中国科学院设备研制项目(编号:YZ201437);广东省科技计划项目(编号:2015A040404042)

摘　　要：【目的】评价双氢青蒿素逆转人结肠癌细胞HCT8/ADR耐药性的能力,研究其逆转耐药的机制。【方法】采用四甲基偶氮唑盐(MTT)法、流式细胞术分别进行细胞毒性、细胞凋亡实验评价双氢青蒿素和阿霉素联合用药的药效,采用Western blot法研究逆转耐药的机制。【结果】双氢青蒿素和阿霉素联用后对人结肠癌耐药细胞有较高的毒性,能诱导耐药细胞凋亡,增强耐药细胞的自噬。【结论】双氢青蒿素能逆转耐药性,恢复耐药细胞对化疗药物的敏感性。Objective To investigate the multidrug-resistance reversal action and mechanism of dihydroartemisin（DHA） on human colon cancer cell line HCT8/ADR. Methods The cytotoxicity of dihydroartemisin combined with doxorubicin（DOX） was determined by methyl thiazolyl tetrazolium（MTT） assay and cell apoptosis was observed by flow cytometry. Western blot assay was used to measure the autophagy. Results The combined treatment with dihydroartemisin and doxorubicin significantly enhanced the cytotoxicity in HCT8/ADR cells and effectively increased the apoptotic level. Autophagy was also induced by the combined treatment,which maybe played a crucial role in the regulation of doxorubicin-sensitization of HCT8/ADR cells. Conclusion The results indicated that dihydroartemisin can reverse multidrug resistance through increasing the doxorubicin-sensitivity of HCT8/ADR cells.

关 键 词：双氢青蒿素 结肠癌/中西医结合疗法 耐药 自噬 细胞培养 细胞凋亡 

分 类 号：R285.5[医药卫生—中药学]